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Resumo 
Os tumores de células renais (RCTs) são os mais letais entre os cancros urológicos 
mais comuns. Devido ao uso generalizado de técnicas de imagem, ocorreu um aumento 
de deteção de pequenas massas renais, enfatizando a necessidade de uma correta 
distinção não apenas entre RCTs benignos e malignos mas também dentro dos RCTS 
malignos, aqueles que vão ser mais agressivos e desenvolver metástases daqueles que 
terão um crescimento mais indolente e passíveis de tratamento mais conservador. A 
metilação das histonas tem sido implicada na tumorigénese renal, contudo o seu potencial 
clínico como biomarcador de metastização em carcinomas de células renais (RCCs) 
permanece por explorar. Deste modo, o principal objectivo deste estudo foi investigar 
histonas metiltransferases (HMTs) e histonas desmetilases (HDMs) expressas 
diferencialmente em RCTs, de modo a avaliar o seu potencial como biomarcadores de 
metastização. Para tal, SETDB2 e MINA foram validadas numa primeira série em 160 
RCTs através de RT-PCR quantitativo. Uma segunda validação numa série de 62 ccRCCs 
foi efetuada para MINA, SETDB2 e mais três enzimas, NO66, SETD3 e SMYD2 com o 
objectivo de aferir o papel destas enzimas na metastização deste subtipo, o mais frequente 
entre os RCTs. Subsequentemente, uma validação adicional da base de dados do The 
Cancer Genome Atlas (TCGA) foi efetuada para MINA, dado que esta enzima apresentou 
os resultados mais promissores. Por último, os níveis de mRNA de todas as enzimas foram 
avaliados nas linhas celulares, e o nível da proteína SETDB2 foi também determinado. 
Especificamente, na primeira série de 160 RCTs, SETDB2 e MINA estão sobre-expressas 
em RCTs comparativamente com tecido renal normal (RNTs) e os seus níveis de 
expressão são mais altos em oncocitomas e carcinomas de células renais cromófobo 
(chRCC) comparativamente ao carcinoma de células renais de células claras (ccRCC) e o 
carcinoma de células renais papilar (pRCC). Os níveis de expressão das duas enzimas 
discriminaram de forma estatisticamente significativa RCTs malignos de benignos. Além 
disto, a SETDB2 demonstrou ter níveis de expressão mais elevados e estatisticamente 
significativos em ccRCCs e pRCCs que não desenvolveram metástases, demonstrando o 
seu potencial como biomarcador de metastização nestes dois subtipos. A análise de 
sobrevivência revelou que a combinação de níveis de expressão de SETDB2 e o Estadio 
(avançado vs. inicial) constituem fatores de prognóstico independentes para a 
sobrevivência livre de doença. Adicionalmente, na segunda série de 62 ccRCCs, os níveis 
de expressão do gene MINA foram estatisticamente mais elevados em ccRCCs que 
desenvolveram metástases, o que poderá auxiliar na definição do prognóstico. Contudo, a 
análise do gene MINA na base de dados do TCGA não revelou diferenças estatisticamente 
significativas entre ccRCCs que desenvolveram metástases e os que não as 
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desenvolveram, contrariamente aos nossos resultados. Tal pode ser devido a diferenças 
nos casos (metástases) incluídos nos estudos, dado que na nossa série foram excluídos 
da análise os casos com metástases identificadas aquando do diagnóstico. Para além 
destes resultados, os níveis de mRNA das cinco enzimas foram avaliados em linhas 
celulares (primárias e metastáticas), contudo devido à alta heterogeneidade dos resultados 
não foi possível retirar conclusões definitivas. Por último, os níveis de proteína SETDB2 
foram avaliados nas linhas celulares, demonstrando haver correlação entre os níveis de 
transcrito e os de proteína. Em conclusão, os resultados do nosso estudo sugerem que os 
genes SETDB2 e MINA são potenciais biomarcadores de metastização em ccRCCs e 
pRCCs, sendo requeridos estudos funcionais para melhor compreender o mecanismo 
biológico subjacente. 
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Abstract 
Renal cell tumors (RCTs) are the most lethal among common urological cancers. 
Due to the widespread use of imaging there has been an increased detection of small renal 
masses, emphasizing the need for accurate discrimination not only between benign and 
malignant RCTs but also among malignant RCTs, specifically between those which will be 
more aggressive and develop metastases and those that will have a more indolent growth 
and may be managed more conservatively. Histone methylation has been implicated in 
renal tumorigenesis, however its potential clinical value as renal cell carcinomas (RCCs) 
metastization biomarker remains mostly unexplored. Thus, the main goal of this study was 
to explore differential expression of histone methyltransferases (HMTs) and histone 
demethylases (HDMs) in RCCs to assess their potential as metastasis biomarker. To 
achieve this goal, SETDB2 and MINA were validated in a first series in of 160 RCTS by 
quantitative RT-PCR. Also, a second validation in a series of 62 ccRCC was performed for 
SETDB2, MINA and three other enzymes, NO66, SETD3 and SMYD2, with the aim of 
evaluating its potential role in metastization of this subtype, which is the most common 
among RCTs. Furthermore, an additional validation using the The Cancer Genome Atlas 
(TCGA) database was performed for MINA, because this enzyme displayed the best results. 
Finally, mRNA levels of all enzymes were assessed in cell lines, as well as SETDB2 protein 
levels.  
Specifically, in the first series of 160 RCTS, SETDB2 and MINA were overexpressed 
in RCTs compared to renal normal tissues (RNTs) and their expression levels were higher 
in oncocytomas and chromophobe renal cell carcinoma (chRCC) compared to clear cell 
renal cell carcinoma (ccRCC) and papillary renal cell carcinoma (pRCC). Moreover, both 
enzymes expression levels discriminated benign from malignant RCTs. Furthermore, 
SETDB2 levels were significantly higher in ccRCCs and pRCCs that did not develop 
metastases, suggesting a potential as metastization biomarker in these two subtypes.  
Survival analysis revealed that combined SETDB2 expression levels and Stage (high vs 
low) were independent prognostic factors for disease-free survival. Additionally, in the 
second series of 62 ccRCCs, MINA expression levels were statistically higher in ccRCCs 
that developed metastases, suggesting that it may assist in the assessment of the 
metastatic potential of ccRCCs. TCGA database analysis for MINA, however, did not show 
statistically significant differences between ccRCCs that developed metastases and those 
that did not, contrarily to our results in the second validation series. This might be due to 
differences in case selection as we excluded from analysis the cases that displayed 
metastases at diagnosis. Furthermore, mRNA levels of all five enzymes were evaluated in 
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cell lines (primary and metastatic) but due to the heterogeneity of the results no definitive 
conclusions could be made. Finally, SETDB2 protein levels were evaluated in cell lines and 
a correlation between transcript and protein levels was depicted. Overall, our results 
suggest that SETDB2 and MINA expression levels are putative biomarkers of metastatic 
behaviour in ccRCCs and pRCCs. Functional studies are required to unveil the underlying 
molecular mechanisms. 
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1. Kidney Cancer  
 
1.1. Pathologoly  
The kidney is an essential organ that is composed of a parenchyma and a collecting 
system. Its main functions are involved with maintaining the body’s homeostatic balance, 
removing waste products from the blood, regulating blood pressure and secreting hormones 
[1].  
Adult kidney cancers can either arise from renal parenchyma, that includes an outer 
cortex and an inner medulla, or from the collecting system, which includes renal pelvis and 
calyces, lined by transitional cells. Those who arise from renal parenchyma are mainly 
adenocarcinomas, currently known as Renal Cell Carcinomas (RCCs), while the ones that 
arise from the collecting system are mostly transitional cell carcinomas (RTCC) [2]. RCCs 
accounts for more than 90% of renal neoplasias, being the most common presentation of 
kidney cancer. In children, the most frequent renal neoplasia is nephroblastoma (Wilms 
tumor), which accounts 1.2% of all kidney cancers [2, 3]. 
 
1.2. Epidemiology 
Kidney cancer is the 14th most common malignancy worldwide and the 8th most 
prevalent cancer in Europe representing 3.5% of all adult malignancies. Regarding 
Portugal, in the year of 2012, 1004 new cases of kidney cancer in both sexes have been 
registered, being the 16th most incident malignancy (Figure 1).  Concerning kidney cancer 
mortality, in 2012, there were 143.406 deaths attributable to this malignancy worldwide. In 
Europe and Portugal, 49.025 and 368 deaths were caused by kidney cancer, respectively 
[4, 5]. 
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Europe, North America and Oceania displayed the higher incidence rates of kidney 
cancer, whereas the lowest rates were observed in Asia and South America and Africa , 
revealing the worldwide variation of kidney cancer incidence (Figure 2) [5]. 
 
 
Furthermore, kidney cancer incidence varies by gender. Comparing the incidence 
of kidney cancer between both genders, men  have a 2 fold risk ratio higher than women 
[4]. 
 
Figure 2 - Incidence for both sexes of kidney cancer worldwide, in 2012. From [5]. 
Figure 1- Incidence and Mortality of most prevalent cancers in Portugal for both sexes, in 
2012. From [5]. 
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According to Globocan predictions, by the year of 2030, the incidence of kidney 
cancer in Europe will increase, being more 22.352 new cases of kidney cancer comparing 
to the year of 2012 (Figure 3) [4].  
 
1.3. Risk Factors 
Until now, Renal Cell Carcinomas’s aetiology remains mostly elusive. Nonetheles, 
there are some well-established risk factors, such as age, gender and geographic 
distribution, smoking, hypertension and obesity [3]. 
 
1.3.1. Demographic Risk Factors 
RCC’s incidence shows differences according to age, sex and race. Typically RCCs 
are diagnosed in the sixth and seventh decades of life. In Europe and the United States, 
the incidence of RCCs increases with age, however a plateau is reached at 70–75 years 
old. This could be due to the less frequent diagnostic testing in this older age group [3, 6]. 
Age standardised incidences, show that men are at an increased risk of developing RCCs, 
with a predominance of 3:2 comparing to females. This could be attributable to differences 
in the prevalence of smoking and occupational exposures. Nonetheless, the incidence of 
RCC is lower among Asians, which suggests a higher risk of RCC in Caucasians compared 
to Asians. Although African countries report the lowest incidence rates, African American 
Figure 3 - Predictions of incidence of kidney cancer for the year of 2030, for both sexes 
in Europe. From [5]. 
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display the highest in United States, suggesting that these racial disparities in incidence can 
be due to differences in frequency of diagnostic and access to health cares [2, 6, 7]. 
 
1.3.2.  - Lifestyle and Occupational Risk Factors 
Cigarette smoking is considered a causal risk factor for RCC by the International 
Agency for Research on Cancer (IARC). Several studies confirmed that smoking increases 
the risk of RCC compared to never smoking. The risk of having RCC increases about 50% 
in male and 20% in females. Cigarette smoking causes chronic tissue hypoxia due to carbon 
monoxide exposure. Furthermore RCC patients were shown to have higher DNA damage 
levels in peripheral blood lymphocytes, including deletions in chromosome 3p, induced by 
a tobacco specific N-nitrosamine [2, 3, 6]. 
Similarly, body weight excess has been established as a risk factor for RCC in 
several case-control and cohort studies. Obesity accounts for nearly 30% of RCCs, 
representing a relative risk in males of 3.3 and in females 2.3. Although the mechanism is 
not clear yet, it is thought that hormonal changes such as increased levels of endogenous 
oestrogens may be the mechanism by which oestrogens induce renal cancer. Moreover, 
high levels of cholesterol and low levels of vitamin D, which are usually seen in obese 
patients, may favour tumor development by an inhibitory effect on immune cells [2, 3]. 
Hypertension is also considered a RCC risk factor. Indeed, several studies reported 
an association with a history of long term hypertension and increasing risk for RCC 
development. As hypertension is a chronic disease, it is estimated that it affects about 20 
to 40 % of the world’s population, being an important RCC risk factor [2, 8]. 
RCC increased risk has also been related with asbestos exposure, organic solvents, 
copper sulphate, polycyclic aromatic hydrocarbons, radiation, viruses and diuretic 
analgesics, however the data currently available is rather inconsistant [3]. 
 
1.3.3. Inheritance and Acquired Cystic Disease/Chronic Dialysis Risk Factors 
The majority of renal cell tumors (RCTs) are believed to be sporadic, however there 
are some specific types of RCC caused by hereditary genetic defects. Overall, 
approximately 2–3% of RCCs are familial. Having a first degree relative with RCT is 
associated with a 2-fold increased risk of developing kidney cancer [6]. There are some 
hereditary RCC syndromes described. 
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Von Hippel-Lindau (VHL) disease is a syndrome of hereditary RCC that is inherited 
through and automosomal dominant trait. It is caused by germline mutations on VHL tumor 
suppressor gene. Patients with this disease present capillary haemangioblastomas of the 
central nervous system and retina, ccRCC, phaeiochromocytoma, pancreatic and inner ear 
tumors [9]. 
Another RCC hereditary syndrome is hereditary papillary RCC. This syndrome is 
caused by activating mutations of the MET oncogene mapped on chromosome 7q and is 
characterized by multiple and bilateral pRCC type 1 [10].  
Hereditary RCC leiomyomatosis is an autosomal dominant syndrome which is 
caused by germline mutations in the FH gene on chromosome 1q. Patients with this 
syndrome usually present benign leiomyomas of the skin and uterus and occasionally 
papillary RCC type 2 and uterine leiomyosarcomas [11].  
Birt-Hogg-Dube (BHD) syndrome results from mutations at BHD that is mapped at 
the chromosome 17p and encodes the protein folliculin. It is characterized by benign skin 
tumors, such as fibrofolliculomas, trochodiscomas and acrchordons, and multiple renal 
tumors [12]. 
Approximately 35 to 47% of patients that need dialysis develop acquired cystic 
disease. Patients with acquired cystic disease can develop a papillary hyperplasia that is a 
precursor of RCC. In fact, about 9% of patients with this syndrome develop RCC, thus 
having a higher risk of having RCC than the general population [13]. 
 
1.4. Clinical Presentation and Diagnosis 
Due to the retroperitoneal localization of the kidney, many renal masses remain 
asymptomatic until the late stages of the disease. The classical triad of flank pain, 
haematuria and palpable abdominal mass used to be the typical clinical presentation of 
RCCs, however, these symptoms are only found in about 6 to 10 % of patients. Bone pain 
and persistent cough are usually symptoms of patients with metastatic disease [14]. 
Additionally, paraneoplastic syndromes, such as hypertension, cachexia and weight loss, 
are present in approximately 30% of patients with symptomatic RCCs [15]. 
Diagnosis of RCCs may occur through physical examination, laboratory findings and 
with most relevance imaging approachs. In fact, more than 50% of RCCs are detected 
incidentally when non-invasive imaging is used in order to investigate other diseases [7]. 
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The proportion of patients with metastatic disease at diagnosis has declined, due to 
improved imaging techniques, more intense screening and incidental case ascertainment. 
As a result, these tumors are generally smaller and have a lower category, comparing to 
symptomatic RCCs. Usually they are small masses (< 4cm diameter), and many clinicians 
refers to them as having benign behaviour. However, adverse features displayed by small 
RCCs, such as invasion of the renal capsule, tumor thrombus and lymph node and distant 
metastasis currently raises concern about the adequacy of management [16, 17]. 
 
1.5. Histopathologycal Subtypes of Renal Cell Tumors 
According to the current neoplasms classification by World Health Organization 
(WHO, 2016), there are four major histological renal cell tumors (RCTs) subtypes: Clear 
Cell Renal Cell Carcinoma (ccRCC), Papillary Renal Cell Carcinoma (pRCC), 
Chromophobe Renal Cell Carcinoma (chRCC) and Oncocytoma, which is a benign tumor. 
WHO classification combines morphological and genetic characteristics, recognizing not 
only these four major subtypes but also some variations or renal cancers with different 
immunophenotypes or molecular changes with clinical implications [18]. 
 
1.5.1. Clear Cell Renal Cell Carcinoma 
Clear Cell Renal Cell Carcinoma (ccRCC) is the most frequent Renal Cell Tumor 
(RCT) subtype, representing 70% to 80% of all RCCs [19]. These tumors are originated 
from cells of the proximal nephron’s tubule and usually have a very vascular stroma, which 
results in haemorrhagic areas. Due to the high lipid content of the tumoral cells, these 
tumors have a typical yellow cut surface. Moreover, small cystic necrotic areas are 
commonly present, being the last one associated with increased aggressive behaviour of 
the tumors [18-20]. 
The average size of detection of ccRCCs is 7cm in diameter, however, the detection 
of smaller lesions is increasing, especially in developed countries, due to the widely use of 
radiologic imaging techniques. Although size itself is not a determinant of malignancy it is 
known that a larger tumor size is often associated with higher metastases frequency [18]. 
The metastatic process in these tumors is commonly hematogeneously, via the vena cava 
primarily to the lung. However, ccRCC is well known by its late metastasis, even after 10 
years or more, and for its metastization to unusual sites [18, 19]. 
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Concerning ccRCC histopathology, these tumours have a diverse architecture. The 
most usual presentation occurs by solid, alveolar and acinar patterns. It is common a regular 
network of small thin-walled blood vessels, and the presence of clear cells due to lipid 
removal during histological processing [18, 21] (Figure 4). Despite this, some tumors may 
contain minority populations of cells with eosinophilic cytoplasm. This is more often in high 
grade tumours and adjacent to areas with haemorrhage or necrosis [18]. 
 
 
 
 
 
 
 
Genetically, the deletion of chromosome 3p is considered to be one of the primary 
events in the carcinogenesis of ccRCC. This genetic alteration occurs in about 70% to 90% 
of RCC [22, 23]. The regions that are frequently lost or inactivated on this chromosome are 
3p12-14, 3p21 and 3p25. The gene that is most commonly involved in the development of 
ccRCC is the tumor suppressor von Hippel-Lindau (VHL), mapped at 3p25. VHL gene is 
consistently inactivated in both sporadic and hereditary renal cancers [24, 25]. Indeed, 
biallelic VHL inactivation is a very high frequency event, that can occur through allelic 
deletion or loss of heterozygosity along with promoter hypermethylation or gene mutation 
[26] . 
VHL protein functions as a tumor suppressor, since it inhibits growth when it is 
reintroduced into cultures of renal cell carcinoma [23].This protein plays a major role in the 
regulation of the transcription factor, hypoxia-inducible factor (HIF), which is a key regulator 
of hypoxia-inducible genes. VHL protein absence induces HIFs accumulation leading to the 
transcription of pro-survival and pro-angiogenic factors, such as Vascular Endothelial 
Growth Factors (VEGF) and Platelet-derived Growth Factor (PDGF) [20, 24]. Moreover, 
mutations in genes involved in chromatin condensation, such as PBRM1, SETD2, KDM5C9, 
KDM6A9 and BAP1, were associated with ccRCC subtype demonstrating a major role of 
the epigenetic deregulation in the development and progression of ccRCC [27]. 
Figure 4 - Microscopic illustration of ccRCC. Original magnification, x100. Haematoxylin and 
eosin stain used. 
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1.5.2. Papillary Renal Cell Carcinoma 
Papillary Renal Cell Carcinoma (pRCC), represents approximately 10% all RCCs, 
being the second most frequent renal cancer [18]. These tumors frequently contain 
haemorrhagic areas, necrosis and cystic degeneration. Usually they are well-circumscribed 
mass enclosed within a pseudo-capsule. Additionally, pRCC subtype is more likely to be 
bilateral and multifocal than other renal parenchymal malignancies [18, 19].  
 
The histology of pRCC is characterized by malignant epithelial cells that form 
papillae and tubules in varying proportions. Herein, the tumor papillae contain a delicate 
fibrovascular core where aggregates of macrophages are common. Moreover, psammoma 
bodies and haemosiderin granules are common [18-21]. There are two morphological types 
of pRCC described: type 1 and type 2 tumors (Figure 5). Type 1 pRCC are more frequent, 
accounting for two thirds of all pRCC.  
These tumors are often multifocal and composed of papillae covered by single 
layered small with scanty cytoplasm. Type 2 tumors include more aggressive variants, with 
cells of higher nuclear grande with eosinophilic cytoplasm and pseudostratified nuclei [18-
21]. 
In addition to these 2 groups, it has been proposed a third group of pRCC, since 
there are pRCC composed entirely by oncocytes that shows clinicalpathologic features 
different from type 1 and type 2 tumors. Also, approximately 5% of all pRCC has 
sarcomatoid dedifferentiation , which is associated with poor prognosis [19].  
Regarding pRCC cytogenetics, its characteristic abnormalities include trisomy or 
tetrasomy of chromosome 7, trisomy of chromosome 17 and chromosome Y’s loss. 
However, other abnormalities were already reported, such as trisomy of 12, 16 and 20, 
which are thought to be related with tumour progression. Loss of heterozygosity at 9p13 
Figure 5 - Microscopic representation of the 2 types of pRCC. [A], pRCC type 1. [B], pRCC 
type 2. Original magnification, x200. Haematoxylin and eosin stain used. 
 [A]                                                               [B] 
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region is also observed being associated with a poorer survival [18]. The mutation of the c-
MET proto-oncogene on chromosome 7 is a usual characteristic of hereditary pRCC, 
however similar somatic mutations were also found in about 13% of sporadic pRCCs. This 
gene encodes a transmembrane receptor (c-Met) that interacts with hepatocyte growth 
factor [28, 29]. 
 
1.5.3.  Chromophobe Renal Cell Carcinoma 
Chromophobe Renal Cell Carcinoma (chRCC) accounts for approximately 5% of all 
RCCs and is originated from the cells of the collecting tubules [18, 30]. Concerning chRCC 
macroscopy, this tumour is typically a solid circumscribed mass, with slightly lobulated 
surfaces. The cut surface is usually homogenous, light brown, without haemorrhage and/or 
necrosis, however it can be seen a central scar in large tumors [18, 21]. 
Microscopically, these tumors are characterized by a solid growth pattern, 
sometimes glandular with focal calcifications and thick-walled blood vessels. Classic 
chRCC histology consists of large polygonal cells with slightly reticulated cytoplasm mixed 
with smaller cells with granular eosinophilic cytoplasm. Some cells are irregular and 
multinucleated, having wrinkled nuclei. Also, perinuclear halos are often seen. The 
eosinophilic variant of chRCC is only composed of eosinophilic cells (Figure 6) [18, 19]. 
Sarcomatoid variants can also be present. The typical features are spindle-like cells, 
high cellularity, cellular atypia associated with necrosis and miscrovascular invasion. This 
particular variant is more common in chRCC than in other RCCs. Overall, having a 
sarcomatoid variant is a sign of poor prognosis [31]. 
 
 
 
 
 
 
  
Figure 6 - Microscopic representation of chRCC. Original magnification, x200. Haematoxylin 
and eosin stain used. 
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Genetic analysis of chRCC has revealed non-random chromosomal losses 
regarding chromosomes 1, 2, 6, 10, 13, 17, and 21. In fact, they have been described in 
roughly 85 to 90 % of chRCCs, showing its potential as a diagnostic marker [31]. These 
massive chromosomal losses usually lead to a hypodiploid DNA index. Moreover, these 
genetic losses may lead to tumor suppressor inactivation, promoting carcinogenisis. Indeed, 
TP53 mutations in 27% of chRCC and  loss of heterozygosity (LOH) around the PTEN gene, 
in chromosome 10 have been reported  by others studies [32, 33].  
 
1.5.4. Oncocytoma 
Oncocytoma is a benign neoplasm that represents 3 to 5% of all primary epithelial 
neoplasms of the adult kidney. Macroscopically, these tumours are well-circumscribed and 
nonencapsulated, displaying a mahogany-brown cut surface. In about 33% of oncocytomas 
a central scar can be seen, being more common in larger tumors. In fact, oncocytomas can 
be fairly large at presentation, but the median size is 4 to 5 cm. Besides the central scar, 
haemorrhagic areas are present in up to 20% of cases [18, 21].  
Regarding histopathology, the predominant cell type is called oncocyte and its 
conformation is round to polygonal with densely granular eosinophilic cytoplasm. The nuclei 
are round and regular with centrally placed nucleolus. Oncocytoma growth pattern is 
characterized by solid compact nests, acini, tubules or microcysts of variable sizes. A 
hypocellularhyalinized stroma is also seen very often (Figure 7) [18, 21]. 
 
 
 
 
 
 
 
At the molecular level, oncocytomas display a mixed population of cells with normal 
and abnormal karyotypes. Some oncocytomas present translocation of t(5;11) and loss of 
chromosome 1 and 14 [18, 34]. 
Figure 7- Microscopic representation of Oncocytoma. Original magnification, x200. 
Haematoxylin and eosin stain used. 
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1.6. Staging 
The tumor-node-metastasis (TNM) classification system is generally recommended 
for clinical and scientific use [35]. TNM system characterizes the degree of tumor local 
extension at the primary site (T), the involvement of regional lymph nodes (N) and the 
presence or absence of metastases (M). The latest version of the TNM classification was 
published in 2010 (Table 1). The prognostic value of the 2010 TNM classification has been 
confirmed by data from a large multi-centre studies with a good level of evidence [7]. 
Table 1 - TNM classification of renal cell tumors. From [23]. 
T – Primary Tumor 
Tx Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
T1 Tumour < 7 cm in greatest dimension, limited to the kidney 
T1a Tumour < 4 cm in greatest dimension, limited to the kidney 
T1b Tumour > 4 cm but < 7 cm in greatest dimension 
T2 Tumour > 7 cm in greatest dimension, limited to the kidney 
T2a Tumour > 7 cm but < 10 cm in greatest dimension 
T2b Tumours > 10 cm limited to the kidney 
T3 Tumour extends into major veins or directly invades adrenal gland or 
perinephric tissues but not into the ipsilateral adrenal gland and not beyond 
Gerota’s fascia 
T3a Tumour grossly extends into the renal vein or its segmental (muscle-
containing) branches or tumour invades perirenal and/or renal sinus (peripelvic) 
fat but not beyond Gerota’s fascia 
T3b Tumour grossly extends into the vena cava below the diaphragm 
T3c Tumour grossly extends into vena cava above the diaphragm or invades 
the wall of the vena cava 
T4 Tumour invades beyond Gerota’s fascia (including contiguous extension 
into the ipsilateral adrenal gland) 
N - Regional lymph nodes 
Nx Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in a single regional lymph node 
N2 Metastasis in more than 1 regional lymph node 
M - Distant metastasis 
M0 No distant metastasis 
M1 Distant metastasis 
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1.7. Treatment 
For localized RCCs, surgery is the standard therapy. Partial nephrectomy is 
preferred over radical nephrectomy, due to the predisposition to chronic kidney disease 
caused by radical nephrectomy [36]. Radical nephrectomy consisting in the entire removal 
of the kidney is performed in patients with locally advanced tumors. Partial nephrectomy 
entails complete tumor resection leaving the largest possible amount of normal functioning 
kidney. There are also thermal ablative therapies, such as cryosurgery and radiofrequency 
ablation, which are alternatives nephron-sparing treatments for patients with localized RCC 
who are not suitable for conventional surgery [23]. Additionally, active surveillance can be 
an alternative for patients with small renal masses that do not show progression [7]. 
For metastatic RCCs, immunotherapy has been the leading treatment. Interferon 
Alpha (INF-α) and Interleukin-2 (IL-2) are the most common immune modulators used in 
clinical practice with response rates of approximately 15 and 20 %, respectively. 
Chemotherapy and hormonal therapy are not standard treatments for RCC, given that the 
response rates to these agents is very limited [37].  
Alongside with immunotherapy, there are novel agents for metastatic RCC (mRCC) 
treatment. Globally, these agents block important pathways in renal carcinogenesis such 
as Vascular Endothelial Growth Factor (VEGF), Platelet- derived Growth Factor (PDGF) 
and Mammalian Target of Rapamycin (mTOR) pathways [38]. 
VEGFR and PDGFR antagonists include tyrosine kinase inhibitors (TKIs), being 
sunitinib and sorafetinib the most widely used. A monoclonal antibody against VEGF-A, 
named bevacizumab is also frequently used. These agents showed a longer progression 
free survival than INF-α [39]. The most common used mTOR inhibitors are everolimus and 
temsirolimus. They both showed a higher overall survival when compared to INF-α. The 
agents mentioned above are all approved by the FDA for mRCC and used in clinical 
practice. Albeit all these therapies for mRCC, the increase on survival rates are only about 
2 to 3 months, showing the need for an improved treatment and the discovery of newer 
agents for effective treatment of metastatic RCC [40, 41]. 
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1.8. Management of Metastatic Renal Cell Carcinoma 
Metastasis is the spread of cells from the primary neoplasm to distant organs or 
lymph nodes. Most deaths from cancer are due to metastases. The improvements in 
diagnosis, surgical techniques, patient care and adjuvant therapies does not seem to be 
enough to improve survival in metastatic cancer [42]. It is known that the major obstacle to 
effective treatment is the biologic heterogeneity of tumor cells. Furthermore, metastases 
may occur in lymph nodes and in different organs, and the microenvironment of the specific 
organ can influence the response of metastatic cells, even their response to therapy [43]. 
Therefore, one of the current major goals of cancer research is the understanding 
the pathogenesis of metastasis, on the systemic, cellular and molecular levels [44]. The 
process of cancer metastasis consists of a long series of sequential, interrelated steps, as 
explained in Figure 8. Each one of these steps can be limiting, given that a failure at any of 
the steps can stop the entire process of metastization [42].  
The management of mRCC still remains a major challenge to the clinician. The 
median survival of patients with metastatic disease is very low (6 to 8 months) and the 5-
year survival rate is below 10%. One of the reasons for this survival rate is the ineffective 
effect and response rate of <5% of cytotoxic chemotherapy. The cause of chemoresistence 
in RCC is due to the expression of Multidrug resistance (MDR-1) gene and its protein, p-
glycoprotein [45]. Although RCC is one of the few tumor types that respond to 
immunotherapy, as mentioned above, the response rate of these agents is only about 20% 
(for combined interferon-α and interleukin-2), thus, sustaining the need for research effort 
on metastatic setting of the disease [46]. 
 Albeit the proportion of patients with metastatic disease at diagnosis has declined, 
due to improved imaging techniques, more intense screening and incidental case 
ascertainment, a not negligible number of small RCCs (< 4cm diameter) may present renal 
capsule invasion, tumor thrombus or lymph node and distant metastasis [16, 17]. 
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Indeed, approximately one-third of patients with RCC will eventually develop 
metastasis and as said before, the long term prognosis for these patients is poor [47]. The 
current best therapy for mRCC is still inadequate. Therefore, a better understanding of RCC 
metastization and the identification of new players involved that may be target by 
therapeutic agents is urgently required. 
 
 
  
Figure 8 – Representation of the metastatic process: a - Represents the growth of 
neoplastic cells. b - Extensive vascularization must happen to give tumor nutrients for its growth. 
Also, secretion of angiogenic factors establish a capillary network needed for the tumor. c - Local 
invasion of the stroma tumour cells. As lymphatic channels are thin-walled, they offer very little 
resistance to penetration by tumour cells providing this way the most common route for tumour-cell 
entry into the circulation. d - Detachment and embolization of single tumour cells. Most of the tumor 
cells are destroyed, however some can escape and survive in the circulatory system. Next, they 
become trapped in the capillary of distant organs. e - Extravasation of the tumor cells. f - 
Proliferation in organ parenchyma. In order to continue growing, the tumor cells need to develop a 
vascular network and evade destruction by host defences. Adapted from [42]. 
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2. Epigenetics 
 
The “Epigenetics” field was first described by Waddington in 1942, who defined it as 
“the causal interactions between genes and their products, which bring the phenotype into 
being”. But the word currently refers specifically to heritable changes in gene expression 
that are not due to any alteration in the DNA sequence [48]. 
Currently, four major epigenetic mechanisms are recognized: DNA methylation, 
non-coding RNAs, histone variants and histones’ posttranslational modifications. As these 
four mechanisms are dynamic, they work together and interact with which other in order to 
regulate gene expression [49]. 
 
2.1. DNA Methylation 
DNA methylation is the most studied epigenetic modification. In humans, DNA 
methylation occurs in dinucleotide CpGs which are cytosines that precede guanines. It 
consists in the addition of a methyl group at the 5’ position of a cytosine ring within CpG 
dinucleotides. These CpG sites are not randomly distributed in the genome, instead there 
are CpG-rich regions named CpG islands [48]. CpG islands are characterized by a CG 
content of at least 50% and a ratio of observed/expected CpG dinucleotides of at least 0.6 
and span at the 5’ end of the regulatory region of many genes (about 60%). This alteration 
is catalysed by enzyme DNA methyltransferases (DNMTs), which catalyse the transfer of a 
methyl group from S-adenosyl methionine to DNA. There are three main DNMTs: DNMT1, 
which maintains the existing methylation patterns following DNA replication, and DNMT3A 
and DNMT3B, de novo enzymes that target previously unmethylated CpGs [50]. 
Methylation of CpG islands is associated with gene silencing. This can happen by 
recruitment of methyl-CpG-binding domain (MBD) proteins that recruit histone modifying 
and chromatin remodelling complexes to methylated sites. Besides this, DNA methylation 
can also directly inhibit transcription by blocking the recruitment of DNA binding proteins 
from their target sites [49]. Hence, DNA methylation is an important regulatory mechanism 
of gene transcription [51]. 
 
2.2. Non-coding RNAs 
In recent years, attention has been focused in non-coding RNAs (ncRNAs).  Non-
coding RNAs are a class of RNAs that do not encode proteins but has several functions in 
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the cells. In fact, It has become increasingly evident that the portion of the genome that 
does not code proteins has a crucial function both for normal development and physiology 
and for disease [52]. Specifically, non-coding RNAs have functional relevance in many 
cellular pathways such as splicing, chromosome dynamics, RNA editing, inhibition of 
translation, mRNA destruction, X-chromosome silencing in females and DNA imprinting. 
Depending on their length, function and interactions, ncRNAS can be distributed in different 
classes, being the most widely studied microRNAS (miRNAS) [53]. 
 MicroRNAs are small non-coding RNAs, with 18 to 25 nucleotides (nt) in 
length, which are synthesized and processed in the nucleus and then exported to the 
cytoplasm where they regulate gene expression. Indeed, it is estimated that miRNAs control 
approximately 30% of human genes [54]. Initially, miRNAs have been reported as negative 
regulators of mRNA expression: repress the mRNA translation either by degradation or 
inhibition of mRNA, depending on the accuracy of matching miRNA-mRNA [55]. However, 
in recent years, it was suggested that they could also act as positive transcription regulators. 
Moreover, one miRNA can target many mRNAs, which in turn can be targeted by several 
miRNAs [56]. 
In cancer, as in other diseases, aberrant miRNAs expression has been widely 
reported. Although a trend to a global miRNAs downregulation is seen in cancer, 
upregulation has also been described [52, 57]. Regarding miRNAs’ role in tumorigenesis, 
they can act as an oncogene (oncomiRs) or tumor-supressors, depending on the target 
genes and the neoplastic context [58]. 
 
2.3. Histone Variants 
The substitution of canonical histones by sequential similar non-allelic histones 
variants is the less studied epigenetic mechanism. Histone variants are called “replacement 
histones” because they substitute the canonical histones during development and 
differentiation, establishing cell identity [59, 60]. Thus, impacting in nucleosome-DNA 
stability and in the efficiency of protein complexes responsible for histone disposition and 
displacement in the nucleosome [61]. 
 
2.4. Posttranslational Modifications of Histone Proteins  
Each nucleosome, the basic unit that composes chromatin, is composed by an 
octamer of four core histone proteins (H3, H4, H2A and H2B) around which 146bp of DNA 
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is wrapped. Histones are small basic proteins that contain a globular C-terminal domain and 
a unstructured N-terminal tail [62]. The N-terminal tails of histones protrude from the 
nucleosome and can be altered by different post-translational modifications which are 
catalysed by various histone-modifying enzymes. Until now, at least 16 different post-
translational histone modifications (PTMs) have been reported, being the most well-known, 
acetylation, methylation, ubiquitination and phosphorylation [63]. These modifications 
regulate key cellular processes such as transcription, replication and repair, and are 
performed by enzymes named “chromatin writers”. On the other hand, PTMS are removed 
by “chromatin erasers” and recognized by “chromatin readers” in a highly regulated manner 
( Figure 9) [64, 65].  
 Histone modifications affect the chromatin structure by either changing the 
accessibility of chromatin (heterochromatin or euchromatin) or by interfering with other 
proteins’ recruitment to the chromatin. Moreover, PTMs not only determine the accessibility 
to specific DNA loci but also provide an informative platform for the recruitment of epigenetic 
regulators [63]. All of these distinct combinations of PTMs of histone tails are named 
“Histone code” and along with DNA methylation regulate gene activation or inactivation [48]. 
  
Figure 9 – Schematic representation of chromatin writers, readers and erasers: Epigenetic 
writers can be histone acetyltransferases (HATs), histone methyltransferases (HMTs), protein 
arginine methyltransferases (PRMTs) and kinases. Epigenetic readers are bromodomains, 
chromodomains and Tudor domains. Epigenetic erasers are histone deacetylases (HDACs), lysine 
demethylases (KDMs) and phosphatases. From [66]. 
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Regarding histone acetylation, this PTM is “written” by histone acetyltransferases 
(HATs) and “erased” by histone deacetylases (HDACs). The gene transcriptional activ ity is 
regulated due to alterations in the electrostatic charge of the nucleosomes [66]. Therefore, 
states of euchromatin are hyperacetylated which decreases the histone-DNA affinity and 
allows gene transcription, whereas hypoacetylation is a characteristic of heterochromatin 
[67]. 
Concerning histone methylation, the “writers” are histone methyltransferases (HMT) 
and the “erasers” are histone demethylases (HDM). Histone methylation promote gene 
activation or repression depending on the residue and the number of methylated molecules 
added (mono-, di-, or tri-) [68]. For example, trimethylation of lysine 4 on histone H3 
(H3K4me3) is very common at transcriptionally active gene promoters. On the other side, 
trimethylation of H3K9 (H3K9me3) and H3K27 (H3K27me3) is present at gene promoters 
that are transcriptionally repressed. These two last modifications together constitute the 
principal silencing mechanism in mammalian cells [66, 69]. 
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1. Brief Contextualization 
 
The work presented in this Master Thesis arises from a previous project developed 
at the Cancer Epigenetics and Biology Group (GBEC) [70], which aimed to explore the role 
of HMTs and HDMs in kidney cancer . Thereby, in order to identify what HMTs and HDMs 
displayed an abnormal expression pattern during renal carcinogenesis, the expression 
levels of 58 HMTs and 29 HDMs were evaluated in 5 chRCCs, 5 oncocytomas and 5 RNTs. 
The analysis was performed by comparing RNTs and RCTs as well as chRCCs and 
oncocytomas. Globally, HMTs upregulation was observed in RCTs compared to RNTs 
(Figure 10). Conversely, HMTs and HDMs expression levels were downregulated in 
chRCCs compared to oncocytomas. The mRNA levels of the studied genes were 
normalized to the betaglucuronidase (GUSβ) reference gene and the median value of RNTs 
and oncocytomas and chRCCs samples was chosen to calculate the fold variation in gene 
expression between groups, using the comparative Ct method. 
 
 
Based on this screening, MINA and SETDB2 were selected for validation in a series 
of 160 Renal Cell Carcinomas. Additionally, 3 previous validated genes, SMYD2, SETD3 
and NO66 that showed the most differential expression between chRCC and oncocytomas 
and between RCTs and RNTs were also assessed in a series of 31 ccRCCs that developed 
metastases comparing to 31 ccRCCs that did not developed metastases.  
 
. 
.  
Figure 10 - Fold variation graphics adapted from [70]. Dark bars represent methyltransferases 
and white bars represent demethylases. Black arrows : Enzymes newly selected; Blue arrows: 
Previous selected enzymes. 
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1. Aims 
 
Among common urological cancers, RCTs are the most lethal. Despite modern imaging 
methods and early diagnosis, one third of RCC patients develop metastatic disease, which 
is the major cause of mortality. Even with the use of targeted therapies, long-term prognosis 
for mRCC patients is poor, with a median survival less than two years. Due to the 
widespread use of imaging, there is an increase in small renal masses detection, requiring 
accurate tools for discrimination of small tumours that will display aggressive behaviour 
through metastization and those that will have a more indolent grow. Indeed, although 
tumours with less than 4cm rarely metastasize to distant organs, some do and carry a 
dismal prognosis. This emphasizes the need for accurate distinction between those tumor 
subsets.  
Furthermore, recent data implicated chromatin machinery deregulation in renal 
neoplastic transformation, entailing the selection of five HMTs and HDACs to investigate 
their role in RCC metastization and their potential as prognostic biomarker in RCCs. To 
achieve this, several goals were established: 
I. Validate MINA and SETDB2 in a large series of  160 RCCs; 
II. Ascertain the correlation between MINA and SETDB2 expression with 
clinicopathological parameters; 
III. Assess MINA, SEDTB2, NO66, SETD3 and SMYD2 expression levels in a 
series of ccRCCs  including patients that developed metastasis; 
IV. Correlate MINA, SETDB2, NO66, SETD3 and SMYD2 expression levels with 
clinicopathological variables; 
V. Compare the data obtained in our series with that of TCGA database cohort of 
patients; 
VI. Correlate SETDB2 transcript with protein levels in kidney cell lines. 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
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1. Patients and Sample Collection 
 
A series of 160 RCTs comprising 40 cases of each subtype (ccRCCs, pRCCs, 
chRCCs and oncocytomas) were prospectively collected from patients consecutively 
diagnosed and submitted to nephrectomy at the Portuguese Oncology Institute of Porto. As 
controls, 13 renal normal tissue (RNT) samples were collected from patients subjected to 
nephrectomy due upper urinary tract urothelial carcinoma. All tissues were immediately 
frozen after surgery and stored at -80ºC. Sampling of more than 70% of malignant cells 
confirmed by two slides stained with hematoxylin and eosin (H&E) taken before and after 
frozen section collection for RNA extraction. Relevant clinical data was also collected from 
clinical charts.  
An independent series of 62 ccRCCc comprising 31 ccRCCs that have developed 
metastasis and 31 ccRCCs that did not progress were also collected. All specimens were 
immediately frozen after surgery and stored at -80ºC. Sampling of more than 70% of 
malignant cell was confirmed by the same method as described before. Relevant clinical 
data was also collected from clinical charts. Samples were paired based on tumor size, 
gender, age and pathological stage. 
This study was approved by institutional ethics review board (CES-IPOPFG-EPE 
518/10). 
 
2. RNA Extraction 
 
For RNA extraction, samples were suspended in TRIzol® reagent (Invitrogen™, 
Cat.#15596018) and  chloroform ( Merk Milipore, Cat.#MCX10601) was added after the 
cells were lysed. RNA concentrations and purity ratios were determined using a NanoDrop 
ND-1000 spectrophotometer (NanoDrop Technologies). Samples were stored at -80ºc. 
 
3. Validation of Selected Enzymes 
 
MINA and SEDTB2 mRNA levels were evaluated in two independent series of 160 
RCTs. Also in a second validation series of 62 ccRCCs, all five enzymes were evaluated. 
 For the validation in a series of 160 RCTS a total of 300ng was reverse transcribed 
and amplified using TransPlex®Whole Transcriptome Amplification Kit (Sigma-Aldrich®, St. 
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Louis, MO, United States) with subsequent purification using QIAquick PCR Purification Kit 
(QIAGEN, Germany), according to manufacturer’s instructions. MINA and SETDB2 mRNA 
levels were evaluated using TaqMan® Gene Expression Assays [Applied Biosystems®, 
Hs99999908 m1 (GUSβ), Hs01126272 m1 (SETDB2), Hs00262155 m1 (MINA)] according 
to manufacturer’s instructions. For each sample, expression levels were normalized using 
one internal reference gene, GUSβ, according to the formula: target gene relative 
expression = target gene expression level/ GUSβ expression level. Each plate included 
multiple non-template controls and serial dilutions of a cDNA Human Reference Total RNA 
(Agilent Technologies, Cat.#750500) in order to construct a standard curve. 
 For the validation in the series of 62 ccRCCs and cell lines, 1 μg of total RNA was 
reverse transcribed using the High Capacity cDNA Reverse Transcription kit according to 
the manufacturer’s instructions. MINA, SETDB2, SMYD2, NO66 and SETD3 mRNA levels 
were evaluated using TaqMan® Gene Expression Assays [Applied Biosystems®, Cat.# 
4331182 Hs00220210 m1 (SMYD2), Hs00260120 m1 (SETD3), Hs02743012 s1 (NO66), 
Hs99999908 m1 (GUSβ), Hs01126272 m1 (SETDB2), Hs00262155 m1 (MINA) ] according 
to manufacturer’s instructions. For each sample, expression levels were normalized using 
one internal reference gene, GUSβ, according to the formula: target gene relative 
expression = target gene expression level/ GUSβ expression level. Each plate included 
multiple non-template controls and serial dilutions of a cDNA Human Reference Total RNA 
(Agilent Technologies, Cat.#750500) in order to construct a standard curve. 
 
4. Cell Culture  
 
SMYD2, NO66, SETD3, SEDTB2 and MINA mRNA levels were also assessed in 
the renal cell lines, including metastatic and primary tumors cell lines, available in the 
laboratory. Metastatic cell lines are Caki-1 (metastasis from ccRCC) and ACHN (metastasis 
from pRCC). Caki-2, 769-P, 786-O and A-498 are primary ccRCCs cell lines. Additionally, 
HK-2, a normal kidney cell line and HEK 293 an embrionary kidney cell line were also 
evaluated. 
Concerning culture media conditions, Caki-1 and Caki-2 were grown using McCoy’s 
5A modified Liquid Medium (EMD-Millipore ; 786-O, 769-P, HK-2 and HEK 293 were 
maintained in RPMI 1640 Liquid Medium (EMD-Millipore); ACHN and A-498 were grown 
using Eagle’s Minimum Essential Medium (EMD-Milipore). All cell lines were supplemented 
with 10% of Fetal Bovine Serum (FBS) Superior (EMD-Millipore) and 1% 
Penicillin/Streptomycin (GIBCO®, Carlsbad, CA, USA) and maintained in cell culture flaks 
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at 37ºC and 5% CO2 at a humidifying chamber. The cells were harvested using TrypLE™ 
Express (GIBCO®). All cell lines were routinely tested for Mycoplasma spp. contamination. 
 
5. Protein Extraction and Quantification 
 
Total protein was extracted from cell lines using Kinexus Lysis Buffer with Lysis Buffer 
Cocktail (Kinexus Bioinformatics Corporation, Vancouver, British Columbia, Canada).In 
short, the protocol begins with removal of the growth medium from cell culture flasks. Next, 
the cells were washed two times with PBS. The cells were scrapped from the flasks with a 
cell scrapper (Santa Cruz Biotechnology Inc.) and then transferred to a 1.5 mL tube. Later, 
the tubes were sonicated on ice for 6 cycles of 15 seconds, having a 15 seconds gap 
between each cycle. Then the tubes were centrifuged for 30 mins at 13,000 rpm at 4ºC and 
the supernatant was transferred to a new tube. Protein concentration was assessed using 
Pierce BCA Protein assay Kit (Thermo Scientific, Waltham, MA, USA), following 
manufacturer’s instructions. All protein samples were stored at -80ºC. 
 
6. SDS-PAGE and Western Blot  
 
SETDB2 Protein expression was assessed in kidney cell lines by Western Blot 
analysis. Summarily, loading buffer was added in 30µg of total protein and then denatured 
for 5 minutes at 95ºC. After centrifugation, samples were loaded in a polyacrylamide gel 
composed by a 10% running gel [10% (w/v) acrylamide/bis-acrylamide solution, 0.375M 
Tris-HCl pH=8.8, 0.1% (w/s) SDS, 0.1% (w/s) APS and 0.04% (v/v) TEMED] and a 4% 
stacking gel [4% (w/v) acrylamide/bisacrylamide solution, 0.062M Tris-HCl pH=6.8, 0.1% 
(w/s) SDS, 0.1% (w/s) APS and 0.25% (v/v) TEMED]. Protein separation was performed in 
a drive Mini-Protean 3 Eletrophoresis System (BioRad, Hercules, CA, USA) at 120V in a 
running buffer (0,025M Tris, 0192M glycine and 0.1% SDS, pH=8.3). After SDS-PAGE, 
proteins were blotted in PVDF membranes (Bio-Rad Laboratories Inc., Hercules, CA, USA) 
that were previously activated in 20% (v/v) methanol. The membranes and filter papers 
were incubated for 20 minutes and the gel for 10 minutes at room temperature in transfer 
buffer [0.025m Tris, 0.192M glycine and 20% (v/v) methanol. Protein blotting was made in 
Trans-Blot® Turbo™ Transfer System (BioRad, Hercules, CA, USA) for 8 minutes at 25V. 
After incubation for an hour in a blocking solution 5% (w/v) BSA (ChemCruz™ 
Biochemicals, Santa Cruz Biotechnology Inc., ) in 0.01M Tris-buffered saline containing 
0.1% (v/v) Tween 20], membranes were incubated overnight at 4ºC with primary antibody 
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SETDB2 (1:1000; # 05-1952 ; EMD-Millipore) in blocking solution. Membranes were 
washed in TBS with Tween and incubated for 1 hour with Goat Anti-Mouse IgG (1:4000; 
BioRad, Hercules, CA, USA). The blots were developed using Western BrightTM ECL- 
spray (Advansta Corporation, Menlo Park, CA, USA) and exposed to AmershamTM 
Hyperfilm ECL (GETM Healthcare, Buckinghamshire, United Kingdom). All experiments 
were performed in triplicate. 
 
7.  TCGA Dataset Analysis in pRCC, chRCC and 
ccRCCs Patients 
 
The Cancer Genome Atlas (TCGA) was used to obtain data on MINA expression 
and clinical information, when available, from ccRCCs, pRCCs and ccRCCs patients. All 
expression data from samples hybridized by the University of North Carolina, Lineberger 
Comprehensive Cancer Center, using Illumina HiSeq 2000 RNA Sequencing version 2 
analysis, were downloaded from TCGA data matrix (http://tcga-
data.nci.nih.gov/tcga/tcgaDownload.jsp). This dataset included 533 ccRCC, 290 pRCC and 
66 chRCC. The provided value was pre-processed and normalized according to “level 3” 
specifications of TCGA (see http://cancergenome.nih.gov/dataportal/ for details). 
Biospecimen Core Resources (BCRs) provided the clinical data of each patient. This data 
is available for download through TCGA data matrix (http://tcga-
data.nci.nih.gov/tcga/dataAccesMatrix.htm). 
 
8. Statistical Analysis 
 
In this work, non-parametric tests were used to ascertain statistical significance for 
comparisons made. Mann-Whitney U test (MW) was used in pairwise comparisons and 
Kruskal-Wallis test (KW) was used for comparisons between multiple groups (more than 2). 
These tests were used both in clinical samples and in vitro studies.  
The prognostic significance of available clinical variables (histological subtype, 
pathological stage, Fuhrman grade, age, gender and also HMTs and HDMs expression 
levels) was assessed by constructing disease-specific and disease-free survival curves 
using the Kaplan-Meier method with log-rank test (univariable test). The expression levels 
of SETDB2 and MINA were classified as low or high based on the cutoff value of 25 th 
percentile for SETDB2 expression and 75th percentile for MINA. A Cox-regression model 
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using ENTER method comprising the different variables (multivariable test) was also 
constructed. For this analysis 120 RCC patients were included, which comprised all RCCs 
subtypes. 
Statistical significance was set at p<0.05. Bonferroni correction was applied for 
pairwise comparisons following multiple groups’ analyses, dividing p-value by number of 
groups evaluated (p value < 0.05/n). Statistical analysis was performed using SPSS 
software for Windows, version 22.0 (IBM-SPSS Inc.), and graphs were built using 
GraphPad Prism 6.0 software for Windows (GraphPad Software Inc.). 
 
 
  
 
 
 
 
 
 
 
RESULTS 
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1. Validation of MINA and SETDB2 Expression in a Series 
of 160 RCTs 
 
The validation of MINA and SETDB2 expression levels was performed by quantitative 
RT-PCR in a series of 160 RCTs and 13 RNTs. The results were fully concordant with those 
of the TaqMan® Array from preliminary data. Indeed, both enzymes were significantly 
overexpressed in RCTs compared to RNTs (p<0.0001 for SETDB2 and p<0.05 for MINA; 
Figure 11 A-B).  
 
 
 
 
 
 
 
 
Moreover, MINA and SETDB2 expression levels differed significantly between 
benign and malignant RCTs (Figure 12 A-B). 
 
 
 
  [A]                                                         [B] 
Figure 11 - Expression levels of SETDB2 (A) and MINA (B) in a series of  renal cell tumors 
(RCTs ; n=160) and renal normal tissues (RNTs ;n=13) (**** p<0.0001; * p<0.05). 
[A]                                                            [B] 
Figure 12 - Expression levels of SETDB2 (A) and MINA (B) in a series of benign tumors 
(Oncocytomas, n=40) and malignant tumors (Renal Cell Carcinomas [RCCs], n=120) (**** 
p<0.0001). 
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Moreover, expression levels of both enzymes differed significantly among the four 
RCT subtypes (Table 2). The highest expression levels of SETDB2 and MINA were 
displayed by oncocytomas, followed by chRCC (Figure 13 A-B and Table 2). Conversely, 
pRCC and ccRCC showed the lowest expression levels. 
Pairwise comparisons using Mann-Whitney U test, demonstrated for both enzymes 
that chRCCs significantly differed from pRCCs and ccRCCs. Moreover, SETDB2 and MINA 
discriminated pRCCs from chRCCs and oncocytomas. Furthermore, SETDB2 transcript 
levels differed significantly between chRCCs and oncocytomas (Figure 13 A-B and Table 
2). 
 
 
Table 2 - Pairwise comparison of SETDB2 and MINA expression among renal cell tumor 
subtypes using Mann-Whitney test (M-W test). The values were statistically significant when 
p<0.0125 (Bonferroni’s correction) represented in bold. 
 
 
 SETDB2 (p value) MINA (p value) 
ccRCCs vs pRCCs 0.391775 0.658 
ccRCCs vs chRCCs 2.5822x10-10 1.0701x10-10 
ccRCCs vs Oncocytomas 3.0302x10-12 6.3992x10-12 
pRCCs vs chRCCs 3.7112x10-8 5.6421x10-11 
pRCCs vs Oncocytomas 1.0701x10-10 7.8313x10-12 
chRCCs vs Oncocytomas 0.000332 0.130856 
[A]                                                          [B] 
Figure 13 -Distribution of SETDB2 (A) and MINA (B) expression levels among renal cell 
tumor subtypes. Bonferroni correction was applied and p value was adjusted to 0.0125 (**** 
p<0.0001;** p<0.01). 
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2. Association Between SETDB2 and MINA Expression 
Levels and Clinicopathological Features 
 
The clinicopathological characteristics of patients included in this validation series are 
depicted in Table 3. 
Table 3 - Clinical and Pathological data of patients included in the present study. 
 RCT RNT 
Number of Patients, n  160 13 
Age at diagnosis, median (min-max)  61 (29-86) 67.5 (20-83) 
Gender, n (%)    
     Male  92 (57.5) 7 (53.8) 
     Female 68 (42.5) 3 (23.1) 
     N.A.  3 (23.1) 
Histological Subtype, n (%)    
     ccRCC  40 (25)  
 
N.A. 
 
     pRCC 40 (25) 
     chRCC 40 (25) 
     oncocytoma 40 (25) 
Pathological Stage, n (%)    
     pT1 68 (42.5)  
 
N.A. 
     pT2 23 (14.4) 
     pT3 29 (18.1) 
     pT4 0 (0) 
     N.A. 40 (25) 
Fuhrman Grade, n (%)    
     1 3 (1.9)  
 
N.A. 
     2 41 (25.6) 
     3 58 (36.3) 
     4 18 (11.3) 
     N.A. 40 (25) 
Metastasis, n (%)   
    Clear cell RCC 10 (52.6)  
N.A.     Papillary RCC 7 (36.8) 
    Chromophobe RCC 2 (10.5) 
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No significant differences in gender and age were apparent between patients and 
controls. In malignant tumors, no statistically significant associations were disclosed 
between SETDB2 and MINA expression levels and Fuhrman categories or pathological 
stage (data not shown). In RCTs, expression levels of both enzymes were significantly 
higher in females (Figure 14). Moreover, MINA expression levels significantly associated 
with patient’s age (p=0.015)] using 75 years as cut-off. 
 
In ccRCCs and pRCCs, SETDB2 expression levels differed significantly between 
patients that developed metastases (YES) from those patients that did not (NO) (Figure 15). 
 
 
 
 
[A]                                                            [B] 
[A]                                                           [B] 
Figure 14 - Expression levels of SETDB2 (A) and MINA (B) in a series of 160 RCTs 
distributed by gender (** p<0.001; * p<0.05). 
Figure 15 - Expression levels of SETDB2 (A) and MINA (B) in a series of 80 ccRCCs and  
pRCCs distributed by presence or absence of metastases after diagnosis. No statistical 
association was found for MINA expression levels (* p<0.05). 
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3. Assessment of SETDB2 and MINA Expression 
Levels as Prognostic Markers 
 
The median follow-up of RCC patients was 175 months (range: 2-375 months). A 
total of 15 patients have died from RCC during this period. Disease-specific survival (DSS) 
analysis showed that low SETDB2 and MINA levels were significantly associated with worse 
outcome (p<0.01 and p<0.05 respectively; supplementary Figure 1). Concerning disease-
free survival (DFS) analysis, low SETDB2 levels significantly associated with shorter time 
to progression (p<0.0001). The same trend was observed for MINA, but statistical 
significance was not reached (p=0.055; Figure 16). Because DFS endpoint is time to 
recurrence, which in RCC refers to development of metastases, subsequent analysis 
focused on this clinical variable.  
 
 
 
 
 
 
 
 
 
 
 
 
In univariable analysis, higher pathological stage (>pT3) associated with shorter 
survival (Figure 17), whereas gender, age, subtype and Furhman grade did not disclose 
any prognostic value within the available follow-up time. 
 
 
 
[A]                                                                  [B] 
Figure 16 - Kaplan-Meier estimated disease-specific survival curves of 120 RCC patients 
according to expression levels of SETDB2 (A) and MINA (B). The results of RT-qPCR presented 
were categorized using first quartile (25th percentile) value as cutoff for SETDB2 (p=0.00009) and 
using 75th percentile value as cut off for MINA (p=0.055). 
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In multivariable analysis, a model for assessment of prognostic value, based on an 
automatic variable selection algorithm (ENTER), was performed. Thus, a final model 
including SETDB2 expression levels and pathological stage (High vs Low) was predictive 
of disease-free survival. Moreover a higher risk of recurrence (metastization) was defined 
for patients with higher pathological stage and lower SETDB2 expression levels (Table 4). 
 
Table 4 - Prognostic factors in Disease-free Survival obtained by Cox regression 
multivariable analysis using ENTER method. The high and low levels of SETDB2 mRNA expression 
were categorized using 25th percentile value as cut-off. 
Prognostic Factor Hazard 
Ratio 
(HR) 
95% CI for HR Cox regression 
p value 
SETDB2 expression (low levels vs 
high levels) 
4.053 1.604 – 10.241 0.003 
Stage (high stage vs low stage) 2.895 1.154 – 7.262 0.024 
 
 
  
Figure 17 - Kaplan-Meier estimated disease-free survival curve of 120 RCC patients 
according to pathological stage High vs Low (p=0.0013). 
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4. Exploring the role of MINA, SETDB2, SETD3, 
SMYD2 and NO66 in Metastasis Development in a Series 
of 62 ccRCCs 
 
The clinical and pathological characteristics of patients included in this additional ccRCC 
validation series are depicted in Table 5. 
Table 5 - Clinical and Pathological data of patients included in the additional ccRCC 
validation series. 
 ccRCCs that 
developed 
metastases (YES) 
ccRCCs that did not 
developed 
metastases (NO) 
Number of Patients, n  31 31 
Age at diagnosis, median (min-max)  66 (33-82) 62 (39.79) 
Gender, n (%)    
     Male  21 (67.7) 24 (77.4) 
     Female 10 (32.3) 7 (22.6) 
Histological Subtype, n (%)    
     ccRCC  31 (100) 31 (100) 
     pRCC 0 (0) 0 (0) 
     chRCC 0 (0) 0 (0) 
     oncocytoma 0 (0) 0 (0) 
Pathological Stage*, n (%)    
     pT1a 0 (0) 0 (0) 
     pT1b 5 (16.1) 7 (22.6) 
     pT2a 5 (16.1) 5 (16.1) 
     pT2b 2 (6.5) 4 (12.9) 
     pT3a 19 (61.3) 15 (48.4) 
     pT3b 0 (0) 0 (0) 
     pT4a 0 (0) 0 (0) 
Fuhrman Grade, n (%)    
     1 0 (0) 0 (0) 
     2 8 (25.8) 11 (35.5) 
     3 15 (48.4) 14 (45.2) 
     4 8 (25.8) 6 (19.4) 
*At diagnosis 
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No significant differences were apparent between the two groups (patients with ccRCCs 
that developed metastases and patients with ccRCCs that did not develop metastases) for 
gender and age (p=0.570 and p=0.402 respectively). Furthermore, no statistically significant 
associations were disclosed between SETDB2 and MINA expression levels and Fuhrman 
categories or pathological stage. 
Moreover, only MINA expression levels differed significantly between metastasized 
ccRCCs and non-metastasized ccRCCs (Figure 18).  
 [A]                                                            [B] 
   [E] 
[C]                                                             [D] 
Figure 18 - SETDB2 (A), MINA (B), SMYD2 (C), SETD3 (D), NO66 (E) expression levels in a 
series of 62 ccRCCs according by development or absence of metastases during follow-up. No 
statistical association was found for SEDTB2, SEDT3, SMYD2 and NO66 and absence of metastasis 
formation (* p<0.05). 
 
Results 
39 
 
5. MINA Expression Analysis in the TCGA Dataset of 
RCC Patients  
 
Further validation of the results depicted for MINA expression was performed in a 
larger and independent dataset from TCGA, including RNAseq expression data from 889 
RCC patients (533 ccRCC, 290 pRCC, and 66 chRCC) – Table 7. 
Table 6 - Clinical and Pathological data of patients included in TCGA database. 
 RCT RNT 
Number of Patients, n  889 129 
Age at diagnosis, median (min-max)  60 (17-90) 61 (28-90) 
Gender, n (%)    
     Male  579 (65.1)  
     Female 286 (32.2)  
     N.A. 24 (2.7)  
Histological Subtype, n (%)    
     ccRCC  533 (60)  
 
N.A. 
 
     pRCC 290 (32.6) 
     chRCC 66 (7.4) 
     oncocytoma 0 
Pathological Stage, n (%)    
     pT1 454 (51.1)  
 
N.A. 
     pT2 103 (11.6) 
     pT3 189 (21.2) 
     pT4 101 (11.4) 
     N.A. 42 (4.7) 
Metastasis, n (%)   
    Clear cell RCC 79 (87.8)  
N.A.     Papillary RCC 9 (10) 
    Chromophobe RCC 2 (2.2) 
RCT: Renal cell tumors; RNT: Renal normal tissue 
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Contrarily to our results, significantly lower expression levels were found in RCT 
compared to RNT (Figure 19A). Similar to our results, however, pairwise comparisons 
demonstrated that MINA expression levels were significantly higher in chRCCs compared 
to ccRCCs and pRCCs. Furthermore, MINA expression levels differed significantly between 
chRCC and ccRCC, chRCC and pRCC and ccRCC and pRCC (Figure 19B). 
 
 
 
 
 
In the ccRCCs of the TCGA database, no statistically significant difference was 
disclosed for MINA expression levels between the group of patients that developed 
metastases (YES) and the patients that did not develop metastases (NO) (Figure 20). 
  
[A]                                                                [B] 
Figure 19 - Expression levels of MINA in a series of RCTs (n=889) and RNTs (n=129) (**** 
p<0.0001) (A). Distribution of MINA expression levels across renal cell carcinoma subtypes. 
Bonferroni correction was applied and p value was adjusted to 0.0125 (**** p<0.0001;*** p<0.001) 
(B). 
 
Figure 20 - MINA expression levels in a series of 533 ccRCCc distributed by presence or 
absence of metastases after diagnosis. No statistical association was disclosed. 
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6. Validation in Renal Cell Lines 
 
SETDB2, MINA, SETD3, SMYD2 and NO66 expression profile was also assessed in 
RCC cell lines (Caki-1, 786-O, Caki-2, ACHN, 769-P, A-498) and normal kidney cell lines 
(HK-2 and 293-HEK) (Table 7) by quantitative RT-PCR (Figure 21).  
Table 7 - Cell lines subtypes 
Cell line Disease 
Caki-1 Metastasis of Clear cell RCC 
Caki-2 Clear cell RCC 
ACHN Metastasis of papillary RCC 
A-498 Clear cell RCC 
786-O Clear cell RCC 
769-P Clear cell RCC 
HK-2 Normal kidney 
293-HEK Embrionary kidney 
 
 
SMYD2 mRNA levels were higher in Caki-1 and ACHN cells, which are both derived 
from metastatic cells. NO66 displayed higher mRNA levels in 786-O cell line. The highest 
transcript levels of SETD3, SETDB2 and MINA were displayed by 769-P cell line. Globally 
all enzymes displayed lower mRNA levels in Caki-2 cell line, a primary cell line from ccRCC, 
comparing to the normal kidney cell line, HK-2. 
Figure 21 - Relative expression of SMYD2, NO66, SETD3, SEDTB2, MINA in all cell lines 
compared to the normal kidney cell line (HK-2). 
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7. Assessment of SETDB2 Protein Levels in Cell Lines 
 
SETDB2 mRNA levels and SETDB protein levels, determined by western blot, were 
compared. 769-P and ACHN cells displayed higher mRNA levels (Figure 21). Furthermore 
lower SETDB2 mRNA transcript was displayed by Caki-1 and Caki-2 cell lines. The same 
trend was observed for SETDB2 protein (Figure 22) as Caki-1 and Caki-2 cell line did not 
show any protein expression (undetected). 
 
 
 
 
 
 
The evaluation of the protein levels of the SMYD2, NO66 and SETD3 was not made 
since it was already assessed in a previous work. For MINA, this process is still ongoing. 
SETDB2 presented the best results in our first series of validation, and for this reason we 
have focused in this enzyme. 
 
 
 
Figure 2 - SETDB2 transcript (A) and protein (B) expression levels in kidney cell lines. 
Transcript expression was calculated using GUSβ as endogenous control gene and protein 
expression using Actin as endogenous control. Three biological independent samples were 
performed, each of them run in triplicate. The order of the Western blot is the same of the relative 
expression graphic. 
[A]                                                                   [B] 
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Over the last decade, due to the widespread of imaging methods, the frequency of 
incidental detection of RCTs has significantly increased. Indeed, the incremented use of 
Computed Tomography (CT), Magnetic Resonance Imaging (MRI) or Ultrasound (US) 
allowed for the detection of small and early stage renal tumours, thought to be less 
aggressive. However, lymph node and distant metastases occur even in small RCCs, 
supporting the need of proper evaluation and adequate treatment of these small RCCs [16]. 
Distant metastases are the main cause of the high mortality rate of RCCs. In fact, these 
carcinomas are the most lethal among the common urologic cancers [71]. Thus, there is an 
urgent need of biomarkers capable of accurately discriminate tumours that will metastasize 
from those that will not, especially among those of small dimension (mostly pT1). 
Epigenetic-based biomarkers may assist in diagnosis, prognosis stratification and 
prediction of response to targeted therapy [72]. In fact, histone modifications and chromatin 
modulators have been demonstrated to play an important role in cancer progression [73]. 
In RCC, certain histone modifications associate with progression-free survival and also 
correlate with pathological characteristics of tumors [74]. In addition, defects in epigenetic 
enzymes, including chromatin remodelers and chromatin packaging have been also 
implicated in the development of RCTs, reflecting the role of these mechanism in the 
development of renal cancer [75]. In this context, we investigated whether HMTs or HDMs 
expression could be metastization biomarkers in RCC, and unveil the role of histone 
methylation in renal tumorigenesis, especially in the metastatic process. To achieve that 
goal, MINA and SETDB2 were selected for validation in a series of 160 ccRCCs. An 
additional assessment in a series of 62 ccRCCs and in kidney cell lines was performed for 
all enzymes. Furthermore, an external validation, using TCGA dataset was carried out for 
MINA, since this enzyme displayed the best results in our second validation series.  
In the first validation series (160 RCCs), SETDB2 and MINA expression levels were 
significantly upregulated in RCTs, among which oncocytomas displayed the highest 
expression levels. These results are in line with those of the previously published array and 
is in agreement with their putative role in cancer [70]. Both enzymes showed lower 
expression levels in ccRCC, however, it did not significantly differ from pRCCs. This finding 
might be due to the common origin of ccRCC and pRCC [30]. In fact, tumors with different 
tubular origin (ccRCC and pRCC: proximal convoluted tubule vs Oncocytomas and chRCC: 
cortical collecting duct) showed the most significant differences. However, SETDB2 
expression levels, were significantly different between chRCCs and oncocytomas. Indeed, 
this is a relevant finding, as these two histological subtypes display variable degree of 
morphological overlap, rendering differential diagnosis problematic, particularly between 
oncocytoma and the eosinophilic variant of chRCCs. Moreover, these results are in line with 
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a previous publication [76] although little information is available regarding SETDB2 role in 
tumorigenesis. Recently, it has been shown to be involved in leukemogenesis since it is 
mapped to chromosome 13q14, a region commonly affected by structural aberration in B-
cell chronic lymphocytic leukemia (B-CLL) [77]. Nonetheless, no data is available 
concerning a putative role in metastization of solid tumors. Concerning MINA, high transcript 
or protein levels were reported as a feature of several cancers, including renal cell 
carcinomas, and was associated with poor prognosis [78-84]. Regarding the role of MINA 
in metastization, several other studies showed an association between high MINA 
expression levels and the development of metastasis (lymph node or distant metastases) 
in other cancer models, such as cholangiocarcinoma, gastric adenocarcinoma and 
pancreatic carcinoma [82, 83, 85]. 
We found that SETDB2 expression levels were significantly higher in ccRCC and 
pRCC that developed distant metastases, contrarily to MINA. Only these two subtypes were 
evaluated concerning metastatic behaviour as they represent the most aggressive subtypes 
of RCC, entailing the need for the identification of biomarkers predictive of tumor 
dissemination.  
The prognostic significance of altered SETDB2 and MINA mRNA expression levels 
was assessed through disease-specific and disease-free survival analysis. Interestingly, in 
univariable analysis, both genes low expression levels were associated with worse disease-
specific survival. This result is opposed to previous reports in esophageal and renal cancers 
[76, 84]. Nevertheless, in lung cancer, MINA overexpression was associated with 
favourable outcome [86]. It should be emphasized that our results are mostly influenced by 
pRCC and ccRCC which displayed the lowest expression levels among RCCs. Regarding 
disease-free survival, the results were similar to those of disease-specific survival, although 
only SETDB2 expression levels significantly associated with development of metastases. 
When relevant clinicopathological variables were included in the analysis, only 
SEDTB2 expression levels and Stage retained statistical significance for disease free 
survival. In fact, SETDB2 expression levels could independently predict disease-free 
survival in RCC patients. However, these results should be analysed with caution since only 
19 events (metastases) were found within the follow-up period (7 pRCC, 10 ccRCC and 2 
chRCC). Thus, SETDB2 and MINA expression was evaluated in a second series of RCTs. 
Because ccRCC metastasizes more commonly than any other RCC subtype, the analysis 
was restricted to 62 ccRCCs.  
Three additional enzymes, SMYD2, SETD3 and NO66, known to play a role in RCC 
and previously associated with poor prognosis [70] were also selected. Significantly higher 
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MINA expression levels were found in ccRCCs that developed metastasis, whereas no 
differences were found for SETDB2 expression. This could be due to the differences in the 
validation series (in the first series pRCCs were also analysed), and thus SETDB2 could be 
a biomarker of metastases in pRCCs but not in ccRCCs. Because similar analyses were 
not performed specifically in pRCCs, no definitive conclusions can be made at this time. 
To further validate these results in a completely independent dataset, the TCGA 
basis was surveyed. Although in this dataset statistically significant differences in MINA 
expression levels were also depicted between RCTs and RNTs, higher MINA expression 
levels were found NRTs. This discrepancy might derive from the nature of normal renal 
tissue analysed. Indeed, whereas in the TCGA dataset normal renal tissue was procured 
from morphologically normal renal parenchyma adjacent to tumor, we used RNT from cases 
without RCC. Indeed, we have already demonstrated that normal tissues adjacent to RCC 
harbour epigenetic alterations that may precede neoplastic transformation [87]. Concerning, 
MINA, no differences were apparent between ccRCCs that developed metastases and 
ccRCCs that did not, among the 533 ccRCCs from the TCGA dataset. This result was 
somewhat unexpected but it may be due to differences in follow-up time and enrolment 
criteria, as we excluded from analysis cases that presented metastasis at diagnosis and 
only analysed cases in which metastases developed after an apparently curative surgical 
treatment.  
Based on the previous results, we started to unveil the biological significance of 
altered expression of the five histone modifying enzymes analysed. Thus, we assessed 
mRNA expression levels in kidney cell lines, including benign and malignant. Nevertheless, 
results were very heterogeneous and a clear trend was not apparent, precluding definitive 
conclusions. Because SETDB2 displayed the most promising results as biomarker of 
metastatic behaviour, we further assessed whether an association exists between transcript 
and protein levels. We found that in cell lines there is, indeed, a similar trend between mRNA 
and protein expression. Thus, the assessment of SETDB2 expression might be 
accomplished through immunohistochemistry, allowing for its use on a routine basis, 
although its high expression levels in normal tissues may constitute a challenge. Despite 
several array-based biomarkers have been proposed for RCC, most of them have not been 
validated or have just been validated in a single and limited series of patients [88-91]. 
Nevertheless, prognostic and predictive biomarkers are clearly needed for RCC, allowing 
for improved risk stratification and identification of molecular targets.
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In this study we found that altered expression levels of enzymes involved in histone 
methylation are associated with renal tumorigenesis and metastization. In particular, it was 
found that SETDB2 and MINA, a histone methyltransferase of lysines 4 and 36 of H3 and 
a histone demethylase, were upregulated in RCTs compared to RNTs. Moreover, those two 
genes displayed significantly higher expression levels in oncocytomas and were able to 
distinguish malignant from benign RCTs.  
Additionally, ccRCCs and pRCCs that did not develop metastasis displayed 
significantly higher SETDB2 expression levels than tumors that progressed and 
disseminated, thus suggesting that this enzyme might be a metastasis predictor in these 
RCC subtypes. Moreover, survival analysis revealed that combined SETDB2 expression 
levels and Stage (high vs low), were independent prognostic factors for disease-free 
survival. Conversely, MINA was significantly overexpressed in ccRCCs that developed 
metastasis 
Overall, the present study demonstrated that SETDB2 and MINA are involved in the 
development of metastasis in renal tumorigenesis and might be useful prognostic 
biomarkers.  
 
In the near future: 
We will assess SETDB2 expression in a series of pRCCs to determine whether it is 
also a metastases biomarker of this particular subtype 
We intend not only consolidate some of the results already obtained but also explore 
other mechanisms that might clarify the role of those histone methylation enzymes (MINA 
and SETDB2) in renal tumorigenesis. Thus, genes that might be regulated by these two 
enzymes will be investigated.  
Additionally, because 769-P cells presented the highest MINA expression levels, 
this cell line will be selected for phenotypic assays, such as migration and invasion after 
transfection with sh-MINA, to assess the functional significance of our findings. 
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Supplementary Figure 1 - Kaplan-Meier estimated Disease-specific survival curves of 120 
RCC patients according to SETDB2 expression levels of (A; p=0.002) and MINA (B; p=0.021). The 
RT-qPCR results were categorized using 25th and 75th percentile value as cut-off for SETDB2 and 
MINA, respectively. 
